21:12 , May 9, 2018 |  BC Innovations  |  Translation in Brief

The fate of NK cells

New research is elucidating the relationship between CAR-transfected NK cells’ differentiation states and their cancer-killing potential -- knowledge that Fate Therapeutics Inc. (NASDAQ:FATE) is leveraging for its own cell therapies. In a study published in Cancer...
20:02 , Aug 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Necroptosis strikes again

Adding to the list of necroptosis-related pathologies, a group from Arizona State University has shown the cell death pathway is activated in Alzheimer’s disease. The data, published last month in Nature Neuroscience, identify potential targets...
00:22 , Aug 31, 2017 |  BC Innovations  |  Translation in Brief

Fate’s killer memory

Fate Therapeutics Inc. has published the cell culture methodology behind Fate-NK100, its adoptive memory NK cell therapy in Phase I testing for cancer, and created two off-the-shelf versions of the candidate using iPS cells. According to...